Source: Annual Congress 2011 - Why is epigenetics important for lung disease?



Rating:

Share or cite this content

Citations should be made in the following way:
I. M. Adcock (London, United Kingdom). Histone deacetylases (HDACs) and lung disease. Annual Congress 2011 - Why is epigenetics important for lung disease?

Member's Comments

No comment yet.

Related content which might interest you: Histone acetylation and deacetylation: importance in inflammatory lung diseases Source: Eur Respir J 2005; 25: 552-563 Year: 2005 Decreased histone deacetylase activity in COPD Source: Annual Congress 2008 - Epigenetic modifications in lung disease Year: 2008 Histone deacetylase activity and gene expression in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 316s Year: 2001 Histone deacetylase activity is reduced in COPD. Modulation by theophylline Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003 Steroids and histone deacetylase in ventilation-induced gene transcription Source: Eur Respir J 2007; 30: 865-877 Year: 2007 Global histone H3 lysine 4 (H3K4) dimethylation is an important prognostic factor in lung cancer Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer Source: ERS Lung Science Conference 2017 Year: 2017 Expression of histone deacetylases (HDAC3) and phosporylated-cAMP response element-binding (P-CREB) in bronchial biopsies of asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 470s Year: 2004 LSC - 2017 - Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Histone deacetylases reduction causes defect of Nrf2 response, leading to a reduction of anti-oxidant capacity in COPD Source: Annual Congress 2010 - Pathology and immunology of COPD Year: 2010 LSC Abstract – Histone deacetylase 7 mediated metabolic remodeling: A new crosslink between pulmonary hypertension and cancer Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 The role of histone deacetylase 9 in the imbalance of Th17/Treg in bronchial asthma Source: Annual Congress 2012 - Mechanisms of asthma Year: 2012 Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 DNA methylation and histone modifications of susceptibility in COPD and lung cancer Source: Annual Congress 2011 - Why is epigenetics important for lung disease? Year: 2011 Investigation of the effect of histone deacetylase 2 function on Wegener‘s granulomatosis Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Aberrant expression and activity of histone deacetylases in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 microRNA-223 suppresses histone deacetylase 2 in chronic obstructive pulmonary disease Source: International Congress 2015 – Latest news on miRNAs in pulmonary research Year: 2015 Implication of the histone methyltransferase EZH2 in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 The role of histone deacetylase 2 (HDAC2) and glucocorticoid receptor (GR) isoforms α, β in patients with asthma–COPD overlap syndrome (ACOS) Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013